The authors suggested that O-glycosylation of DR4 and DR5 death receptors in various neoplasias modulates sensitivity to APO2L/TRAIL by promoting ligand-induced receptor clustering and consequent caspase-8 activation [38]. The gene discussed is CASP8; the disease is neoplasm.